PPH NEWS is an education-based resource site that provides information on the health issues surrounding Primary Pulmonary Hypertension (PPH), including what it is, the symptoms, diagnoses, and treatment options.
This website also provides resource to learn more about your legal rights and remedies if you or someone you know has developed PPH due to the use of diet drugs such as Fen Phen.

Get a FREE Evaluation

Select a state Alaska Alabama Arizona Arkansas California Colorado Connecticut Delaware D.C. Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming Select your state to
contact a PPH Lawyer

PPH Lawsuit News

February 1, 2005

Actelion announces the publication of long-term bosentan use in PPH patients

Actelion Ltd announced the publication of the scientific paper evaluation disease outcome of patients with advanced primary pulmonary arterial hypertension receiving Tracleer, or bosentan.

The published results are from the long-term follow-up of the 169 patients with primary pulmonary hypertension (PPH). The study's objective was to evaluate the effect of first-line bosentan therapy followed by additional therapies, if necessary, on survival in PPH patients compared with U.S. National Institute of Health (NIH) estimates.

The outcome in patients receiving first-line bosentan therapy was compared to patient outcome whose disease progression was documented in a historical database of the NIH. Lead investigator, Dr. Vallerie McLaughlin from the University of Michigan, Ann Arbor, said, “The present study suggests that the treatment of first-line bosentan therapy followed by the addition of other pulmonary arterial hypertension (PAH) therapies, if needed, improves survival in patients with advanced primary pulmonary hypertension.”

Dr. McLaughlin believes first-line bosentan should be considered for World Health Organization (WHO) functional class III primary pulmonary hypertension due to the “ease of administration and favorable side-effect profile.”

FREE Case Evaluation for more information.

Click a state below to find a PPH Lawyer in your area.

top